调节性T细胞在胶质瘤介导的免疫抑制中的作用：干预的潜在靶点。
The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
作者信息
Humphries William, Wei Jun, Sampson John H, Heimberger Amy B
机构信息
Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
出版信息
Neurosurg Clin N Am. 2010 Jan;21(1):125-37. doi: 10.1016/j.nec.2009.08.012.
Abstract
The role of regulatory T cells (Tregs) in mediating immune suppression of anti-tumor immune responses is increasingly appreciated in patients with malignancies-especially within the malignant glioma patient population. This article discuss the role and prognostic significance of Tregs within glioma patients and delineates potential approaches for their inhibition that can be used alone or in combination with other immune therapeutics in clinical trials and in the clinical settings of recurrent or residual disease.
摘要
调节性T细胞（Tregs）在介导抗肿瘤免疫反应的免疫抑制中的作用，在恶性肿瘤患者中，尤其是在恶性胶质瘤患者群体中，越来越受到重视。本文讨论了Tregs在胶质瘤患者中的作用和预后意义，并阐述了在临床试验以及复发性或残留性疾病的临床环境中，可单独使用或与其他免疫疗法联合使用的针对Tregs的潜在抑制方法。
相似文献
1
The role of tregs in glioma-mediated immunosuppression: potential target for intervention.调节性T细胞在胶质瘤介导的免疫抑制中的作用：干预的潜在靶点。
Neurosurg Clin N Am. 2010 Jan;21(1):125-37. doi: 10.1016/j.nec.2009.08.012.
2
The role of regulatory T cells in malignant glioma.调节性T细胞在恶性胶质瘤中的作用。
Anticancer Res. 2008 Mar-Apr;28(2B):1143-50.
3
High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with T depletion.高级别胶质瘤相关免疫抑制并不妨碍联合 T 细胞耗竭的治疗性疫苗诱导的免疫反应。
Cancer Immunol Immunother. 2018 Oct;67(10):1545-1558. doi: 10.1007/s00262-018-2214-0. Epub 2018 Jul 27.
4
Basic concepts in glioma immunology.神经胶质瘤免疫学基础概念。
Adv Exp Med Biol. 2012;746:42-52. doi: 10.1007/978-1-4614-3146-6_4.
5
The role of regulatory T-cells in glioma immunology.调节性T细胞在胶质瘤免疫学中的作用。
Clin Neurol Neurosurg. 2014 Apr;119:125-32. doi: 10.1016/j.clineuro.2013.12.004. Epub 2014 Jan 3.
6
Investigation of immunosuppressive mechanisms in a mouse glioma model.小鼠胶质瘤模型中免疫抑制机制的研究。
J Neurooncol. 2009 May;93(1):107-14. doi: 10.1007/s11060-009-9884-6. Epub 2009 May 9.
7
Immunotherapy of diffuse gliomas: biological background, current status and future developments.弥漫性胶质瘤的免疫治疗：生物学背景、现状与未来发展
Brain Pathol. 2009 Oct;19(4):674-93. doi: 10.1111/j.1750-3639.2009.00315.x.
8
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.了解胶质瘤的免疫抑制微环境：机制见解和临床观点。
J Hematol Oncol. 2024 May 8;17(1):31. doi: 10.1186/s13045-024-01544-7.
9
Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model.局部应用富血小板纤维蛋白贴片（PRF-P）抑制小鼠脑胶质瘤模型中调节性 T 细胞的募集。
Mol Neurobiol. 2019 Jul;56(7):5032-5040. doi: 10.1007/s12035-018-1430-0. Epub 2018 Nov 20.
10
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.FoxP3+调节性T细胞在人类胶质瘤中的发生率及预后影响
Clin Cancer Res. 2008 Aug 15;14(16):5166-72. doi: 10.1158/1078-0432.CCR-08-0320.
引用本文的文献
1
Immunologic specificity in glioblastoma: Antigen discovery and translational implications.胶质母细胞瘤中的免疫特异性：抗原发现及转化意义
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv41-iv70. doi: 10.1093/noajnl/vdaf028. eCollection 2025 Sep.
2
The Evidence That Brain Cancers Could Be Effectively Treated with In-Home Radiofrequency Waves.脑癌可通过家用射频波有效治疗的证据。
Cancers (Basel). 2025 Aug 15;17(16):2665. doi: 10.3390/cancers17162665.
3
Immune intrinsic escape signature stratifies prognosis, characterizes the tumor immune microenvironment, and identifies tumorigenic PPP1R8 in glioblastoma multiforme patients.免疫内在逃逸特征可对多形性胶质母细胞瘤患者的预后进行分层，描绘肿瘤免疫微环境，并鉴定致瘤性PPP1R8。
Front Immunol. 2025 Aug 6;16:1577920. doi: 10.3389/fimmu.2025.1577920. eCollection 2025.
4
Advancing vaccine-based immunotherapy in glioblastoma treatment.推进基于疫苗的免疫疗法用于胶质母细胞瘤治疗。
Neurooncol Adv. 2025 Jun 24;7(1):vdaf135. doi: 10.1093/noajnl/vdaf135. eCollection 2025 Jan-Dec.
5
Peripheral biomarkers predict survival in patients with glioblastoma treated with temozolomide.外周生物标志物可预测接受替莫唑胺治疗的胶质母细胞瘤患者的生存期。
Mol Clin Oncol. 2025 Apr 17;22(6):56. doi: 10.3892/mco.2025.2851. eCollection 2025 Jun.
6
Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma.揭示潜力：溶瘤病毒对胶质母细胞瘤神经炎症调节的机制
Explor Target Antitumor Ther. 2025 Feb 24;6:1002294. doi: 10.37349/etat.2025.1002294. eCollection 2025.
7
Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.用于胶质母细胞瘤的生物工程化嵌合抗原受体T细胞/自然杀伤细胞疗法的进展：克服免疫抑制及基于纳米技术增强嵌合抗原受体T细胞/自然杀伤细胞疗法的策略
Bioeng Transl Med. 2024 Aug 31;10(2):e10716. doi: 10.1002/btm2.10716. eCollection 2025 Mar.
8
Comprehensive analysis reveals PLK3 as a promising immune target and prognostic indicator in glioma.综合分析表明，PLK3是胶质瘤中一个有前景的免疫靶点和预后指标。
Oncol Res. 2025 Jan 16;33(2):431-442. doi: 10.32604/or.2024.050794. eCollection 2025.
9
The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies.代谢重编程在胶质母细胞瘤中的影响：免疫格局与治疗策略
Int J Mol Sci. 2025 Jan 14;26(2):669. doi: 10.3390/ijms26020669.
10
Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications.用于先进药物筛选应用的胶质母细胞瘤芯片的最新进展
Small. 2025 Jan;21(1):e2405511. doi: 10.1002/smll.202405511. Epub 2024 Nov 13.
本文引用的文献
1
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.CTLA-4阻断增强转移性黑色素瘤患者中具有临床获益的多功能NY-ESO-1特异性T细胞反应。
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5. doi: 10.1073/pnas.0810114105. Epub 2008 Dec 12.
2
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.一种新型磷酸化 STAT3 抑制剂通过抑制调节性 T 细胞增强 T 细胞对黑色素瘤的细胞毒性。
Cancer Immunol Immunother. 2009 Jul;58(7):1023-32. doi: 10.1007/s00262-008-0618-y. Epub 2008 Nov 11.
3
TLR ligands in the local treatment of established intracerebral murine gliomas.Toll样受体配体在已形成的小鼠脑胶质瘤局部治疗中的应用
J Immunol. 2008 Nov 15;181(10):6720-9. doi: 10.4049/jimmunol.181.10.6720.
4
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.一种新型的信号转导和转录激活因子3激活抑制剂对已形成的中枢神经系统黑色素瘤有效，并能抑制调节性T细胞。
Clin Cancer Res. 2008 Sep 15;14(18):5759-68. doi: 10.1158/1078-0432.CCR-08-0377.
5
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.FoxP3+调节性T细胞在人类胶质瘤中的发生率及预后影响
Clin Cancer Res. 2008 Aug 15;14(16):5166-72. doi: 10.1158/1078-0432.CCR-08-0320.
6
FOXP3 induced by CD28/B7 interaction regulates CD25 and anergic phenotype in human CD4+CD25- T lymphocytes.由CD28/B7相互作用诱导产生的FOXP3调节人CD4+CD25-T淋巴细胞中的CD25及无反应性表型。
J Immunol. 2008 Jul 15;181(2):1025-33. doi: 10.4049/jimmunol.181.2.1025.
7
Immunotherapy of malignant brain tumors.恶性脑肿瘤的免疫治疗
Immunol Rev. 2008 Apr;222:70-100. doi: 10.1111/j.1600-065X.2008.00603.x.
8
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.细胞毒性T淋巴细胞相关抗原4抗体阻断对既往接种过疫苗的癌症患者的免疫和临床影响。
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10. doi: 10.1073/pnas.0712237105. Epub 2008 Feb 19.
9
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.多形性胶质母细胞瘤患者接受替莫唑胺序贯疗程和免疫治疗后的免疫反应：病例研究
Neuro Oncol. 2008 Feb;10(1):98-103. doi: 10.1215/15228517-2007-046. Epub 2007 Dec 13.
10
Interplay between pathogenic Th17 and regulatory T cells.致病性辅助性T细胞17（Th17）与调节性T细胞之间的相互作用。
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii87-90. doi: 10.1136/ard.2007.078527.
Zotero 插件